Marker Therapeutics
MRKR
11 hedge funds and large institutions have $1.14M invested in Marker Therapeutics in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
38% more funds holding
Funds holding: 8 → 11 (+3)
26% more capital invested
Capital invested by funds: $904K → $1.14M (+$233K)
0.1% more ownership
Funds ownership: 0.22% → 0.32% (+0.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boston Financial Management
Boston,
Massachusetts
|
+$216K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$164K |
| 3 |
HNB
Huntington National Bank
Columbus,
Ohio
|
+$1.77K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$1.77K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.55K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $455K | +$164K | +4,655 | +52% |
|
|
NRS
2
Neville Rodie & Shaw
New York
| $413K | – | – | – |
|
|
BFM
3
Boston Financial Management
Boston,
Massachusetts
| $206K | +$216K | +6,105 | New |
|
|
4
BlackRock
New York
| $47K | -$1.27K | -36 | -2% |
|
|
5
UBS Group
Zurich,
Switzerland
| $9K | +$1.55K | +44 | +19% |
|
|
HNB
6
Huntington National Bank
Columbus,
Ohio
| $2K | +$1.77K | +50 | New |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | +$1.77K | +50 | +500% |
|
|
AG
8
Advisor Group
Phoenix,
Arizona
| $1K | – | – | – |
|
|
NSIM
9
North Star Investment Management
Chicago,
Illinois
| $1K | – | – | – |
|
10
Morgan Stanley
New York
| $1K | +$883 | +25 | +2,500% |
|
11
Bank of America
Charlotte,
North Carolina
| – | +$35 | +1 | New |
|
MRKR Hedge Fund Activity: Q1 2018 in Review
11 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2018, worth a combined $1.14M — up 26% from $904K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MRKR positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Boston Financial Management, opening a new position worth an estimated $216K. The largest seller was BlackRock, cutting an estimated $1.27K.
- 11 institutional investors held Marker Therapeutics (MRKR) as of Q1 2018, up from 8 in Q4 2017.
- Funds reported $1.14M of Marker Therapeutics stock for Q1 2018, up 26% quarter-over-quarter.
- 3 funds opened new Marker Therapeutics positions in Q1 2018 and 0 closed out, a net change of +3 holders.
- The largest Marker Therapeutics buyer in Q1 2018 was Boston Financial Management, an estimated $216K added.
- The largest Marker Therapeutics seller in Q1 2018 was BlackRock, an estimated $1.27K sold.
Based on aggregated 13F filings for Q1 2018.